Nature Medicine · 13 July 2026 · From issue 08
An anti-PMEL antibody-drug conjugate with a Gq/11 inhibitor payload in GNAQ/GNA11-mutant melanomas: a phase 1 trial
A new targeted drug shrank tumors in many patients with an aggressive, spreading eye cancer.
Matteo S. Carlino, Ellen Kapiteijn et al.
A new drug shrank tumors in some patients with a rare, hard-to-treat eye cancer that spreads. This cancer often carries specific gene changes that make cells grow out of control. The drug is built to find a marker on cancer cells. It then releases a treatment inside the cell to block that growth signal. In a trial of 66 patients, 13 patients had their tumors shrink a lot. That is about 20 percent. Another 47 patients, or about 71 percent, had some tumor shrinkage. Patients went a median of 7.2 months before their cancer got worse. Serious side effects were uncommon. Only five patients, about 8 percent, had severe treatment-related problems.
Integrity screen: passed (3 checks) Checked 25 August 2026. Read the source
The plain-language reading of this paper is in the full issue, for subscribers.
Read the full issue